公开(公告)号：US20200341437A1

公开(公告)日：2020-10-29

申请号：US16396502

申请日：2019-04-26

申请人： Renchang Dai ,  Guangyi Liu ,  Jun Tan ,  Chen Yuan ,  Yi Lu ,  Zhenjiang Yu ,  Zhiwei Wang

发明人： Renchang Dai ,  Guangyi Liu ,  Jun Tan ,  Chen Yuan ,  Yi Lu ,  Zhenjiang Yu ,  Zhiwei Wang

IPC分类号： G05B13/04 ,  G06F16/901 ,  H02J3/06 ,  H04W52/52

摘要： A power system energy management system with security constrained automatic generation control (SCAGC) is disclosed wherein the power generation output and branch power flow are constrained by security limit. A sub-optimization model is used to calculate SCAGC for each control area in parallel. Graph computing is applied to solve the SCAGC by simplex approach in hierarchical parallel and nodal parallel. The SCAGC is solved heuristically first by combining the equal incremental fuel cost ratio and generation shift factor, and if the heuristics do not converge, a simplex method is used to solve the SCAGC.

公开(公告)号：US20200129527A1

公开(公告)日：2020-04-30

申请号：US16432367

申请日：2019-06-05

申请人： Jun Tan ,  Roland Douglas Shytle ,  Jinhua Wen ,  Darrell Sawmiller

发明人： Jun Tan ,  Roland Douglas Shytle ,  Jinhua Wen ,  Darrell Sawmiller

IPC分类号： A61K31/575 ,  A61K9/00 ,  A61P25/00

摘要： In one aspect, the disclosure relates to compositions of lithium cholesterol compositions, including but not limited to lithium cholesterol sulfate compositions which are useful as therapeutic agents. The disclosure also relates to methods of making lithium cholesterol compositions and pharmaceutical compositions comprising therapeutically effective amounts of the lithium cholesterol compositions. The present disclosure also includes methods of treating one or more clinical neurological conditions with the lithium cholesterol compositions, such as Alzheimer's disease, autism spectrum disorder, bipolar disorder, or other neuropsychiatric disorders.

公开(公告)号：US08906414B1

公开(公告)日：2014-12-09

申请号：US12768380

申请日：2010-04-27

申请人： Roland Douglas Shytle ,  Jun Tan ,  Adam Smith ,  Brian Giunta ,  Cyndy Davis Sanberg

发明人： Roland Douglas Shytle ,  Jun Tan ,  Adam Smith ,  Brian Giunta ,  Cyndy Davis Sanberg

IPC分类号： A61K9/14 ,  A61K9/127

CPC分类号： A61K9/127 ,  A61K31/353

摘要： Compositions and methods of increasing the bioavailability of catechins are presented. Compositions for increasing the bioavailability of catechins include compositions where the catechin is added to a solution of ethanol and water; compositions where the catechin is encapsulated within a nanoparticle; and compositions in which a nanoparticle complex is formed between the catechin and the nanoparticle. Each of these compositions was shown to increase bioavailability of EGCG and is useful in treating diseases such as Alzheimer's and HIV-associated dementia.

摘要翻译： 提出了增加儿茶素生物利用度的组合物和方法。 用于增加儿茶素的生物利用度的组合物包括将儿茶素加入到乙醇和水的溶液中的组合物; 儿茶素包封在纳米颗粒内的组合物; 以及其中在儿茶素和纳米颗粒之间形成纳米颗粒复合物的组合物。 这些组合物中的每一种显示出提高EGCG的生物利用度，并且可用于治疗诸如阿尔茨海默病和HIV相关性痴呆的疾病。

公开(公告)号：US08778894B2

公开(公告)日：2014-07-15

申请号：US14046381

申请日：2013-10-04

申请人： Jun Tan ,  Deyan Luo ,  Roland Douglas Shytle

发明人： Jun Tan ,  Deyan Luo ,  Roland Douglas Shytle

IPC分类号： A01N43/04 ,  A61K31/70 ,  A01N43/16 ,  A61K31/35

CPC分类号： A61K31/7048 ,  A61K31/352 ,  A61K31/353 ,  A61K2300/00

摘要： The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.

摘要翻译： 本发明包括治疗自身免疫性疾病如自闭症，精神分裂症和1型糖尿病的方法。 发现类黄酮，木犀草素，diosmin和diosmin的糖苷配基形式，diosmetin，抑制培养神经元细胞中IL-6诱导的STAT3的激活/磷酸化。 此外，用diosmin治疗的小鼠通过抑制STAT3活化显示IL-6诱导的自闭症表型的显着降低。

公开(公告)号：US20130217045A1

公开(公告)日：2013-08-22

申请号：US13768158

申请日：2013-02-15

申请人： Jun Tan ,  Demian Obregon ,  Huayan Hou ,  Juan Deng

发明人： Jun Tan ,  Demian Obregon ,  Huayan Hou ,  Juan Deng

IPC分类号： G01N33/68

CPC分类号： G01N33/6854 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

摘要： Provided herein is a method for diagnosing Alzheimer's disease in a subject comprising detecting an increase in an amyloidogenic Aβ1-17 antibody in the subject as compared to a control. Further provided herein is a method for testing efficacy of an Alzheimer's disease treatment in a subject comprising detecting a decrease in an amyloidogenic Aβ1-17 antibody in the subject as compared to prior to the treatment.

摘要翻译： 本文提供了一种用于在受试者中诊断阿尔茨海默病的方法，包括与对照相比检测受试者中淀粉样变性Abeta1-17抗体的增加。 本文进一步提供了一种用于测试受试者中阿尔茨海默氏病治疗效果的方法，其包括检测与治疗前相比，受试者中淀粉样变性Abeta1-17抗体的降低。

公开(公告)号：USD686614S1

公开(公告)日：2013-07-23

申请号：US29406666

申请日：2011-11-17

申请人： Jun Tan

设计人： Jun Tan

公开(公告)号：US20110201565A1

公开(公告)日：2011-08-18

申请号：US13093401

申请日：2011-04-25

申请人： Jun Tan ,  Deyan Luo

发明人： Jun Tan ,  Deyan Luo

IPC分类号： A61K31/7048 ,  A61K31/353 ,  A61P3/10 ,  A61P25/18 ,  A61P25/28

CPC分类号： A61K31/7048 ,  A61K31/352 ,  A61K31/353 ,  A61K2300/00

摘要： The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.

摘要翻译： 本发明包括治疗自身免疫性疾病如自闭症，精神分裂症和1型糖尿病的方法。 发现类黄酮，木犀草素，diosmin和diosmin的糖苷配基形式，diosmetin，抑制培养神经元细胞中IL-6诱导的STAT3的激活/磷酸化。 此外，用diosmin治疗的小鼠通过抑制STAT3活化显示IL-6诱导的自闭症表型的显着降低。

公开(公告)号：US20100267733A1

公开(公告)日：2010-10-21

申请号：US12772732

申请日：2010-05-03

申请人： Roland D. Shytle ,  Jun Tan ,  Jared Ehrhart

发明人： Roland D. Shytle ,  Jun Tan ,  Jared Ehrhart

IPC分类号： A61K31/352 ,  A61K31/465 ,  A61K31/4439 ,  A61K31/505 ,  A61K31/4965 ,  A61K31/4985 ,  A61P29/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28

CPC分类号： A61K45/06 ,  A61K31/05 ,  A61K31/352 ,  A61K31/465 ,  A61K2300/00

摘要： Treatment of microglial cells with nicotine and THC synergistically attenuate the microglial activation. Using microglial activation, the combination of THC and nicotine interact synergistically reduced LPS induced TNF-α release, showing that the combination of THC and nicotine clinically have greater efficacy in reducing neuroinflammation with less side effects than either drug given alone. CD40 signaling was found critically involved in pathological activation of microglial cells. This invention is also relevant to peripheral inflammation as well thru macrophages. In addition, other cannabinoids and other nicotinic-like medications currently in development are also covered under this discovery.

摘要翻译： 用尼古丁和THC治疗小神经胶质细胞协同减弱小胶质细胞的活化。 使用小胶质细胞激活，THC和尼古丁的组合相互作用协同降低LPS诱导的TNF-α释放，表明THC和尼古丁的组合在减少神经炎症方面具有更大的功效，副作用少于单独给药的药物。 CD40信号传导被严重影响小胶质细胞的病理活化。 本发明也与周围炎症以及巨噬细胞相关。 此外，目前正在开发的其他大麻素和其他类似烟碱的药物也涵盖在此发现之下。

公开(公告)号：US20100069479A1

公开(公告)日：2010-03-18

申请号：US12552715

申请日：2009-09-02

申请人： Jun Tan ,  Frank Fernandez ,  Nan Sun ,  Roland D. Shytle ,  Jared Ehrhart

发明人： Jun Tan ,  Frank Fernandez ,  Nan Sun ,  Roland D. Shytle ,  Jared Ehrhart

IPC分类号： A61K31/352 ,  C12N5/00 ,  A61P25/00

CPC分类号： A61K31/353 ,  A01K2267/0318 ,  A61K31/4745 ,  A61K36/82 ,  C12N2740/16111 ,  C12N2740/16311

摘要： The invention relates to treatment of neurodegenerative diseases with JAK/STAT pathway inhibitors to eliminate extracellular cell signaling events leading to cell cycle abrogation and/or apoptosis. Primary neurons were administered neurotoxic proteins, such as gp120, Tat, or gp120 and Tat, with or without IFN-γ added, resulting in neuronal death, and simulated neurodegenerative diseases. The neurodegenerative disease is treated using a JAK/STAT pathway inhibitor, including (—)-epigallocatechin-3-gallate (EGCG), to modulate JAK1 or STAT1 phosphorylation, resulting in resistance to gp120 or Tat neurotoxicity. The invention may be used to treat neurons afflicted with HIV-associated Dementia, multiple sclerosis, Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, or Pick's Disease, and may act in conjunction with antiviral treatment, like HAART.

摘要翻译： 本发明涉及用JAK / STAT途径抑制剂治疗神经变性疾病，以消除导致细胞周期消除和/或凋亡的细胞外细胞信号传导事件。 主要神经元被施用神经毒性蛋白质，例如gp120，Tat或gp120和Tat，加入或不加入IFN-γ，导致神经元死亡和模拟的神经变性疾病。 神经变性疾病使用JAK / STAT途径抑制剂（包括（ - ） - 表没食子儿茶素-3-没食子酸酯（EGCG））来调节JAK1或STAT1磷酸化，导致抗gp120或Tat神经毒性。 本发明可用于治疗患有HIV相关性痴呆，多发性硬化，阿尔茨海默氏病，帕金森病，肌萎缩性侧索硬化或皮克病的神经元，并且可以与抗病毒治疗一起起作用，如HAART。

公开(公告)号：US20060223790A1

公开(公告)日：2006-10-05

申请号：US11380223

申请日：2006-04-26

申请人： Doug Shytle ,  Jun Tan ,  Francisco Fernandez

发明人： Doug Shytle ,  Jun Tan ,  Francisco Fernandez

IPC分类号： A61K31/55 ,  A61K31/4439

CPC分类号： A61K45/06 ,  A61K31/4164 ,  A61K2300/00

摘要： A method of treating a subject suffering from a neurodegenerative disease by modulating microglial activation with a therapeutically effective amount of a cholinergic agonist and a cholinesterase inhibitor. In one embodiment of the invention, the cholinergic agonist is nicotine and the cholinesterase is galantamine (a relatively weak acetylcholinesterase inhibitor and a potent allosteric potentiating ligand of nAChRs)

摘要翻译： 通过用治疗有效量的胆碱能激动剂和胆碱酯酶抑制剂调节小胶质细胞活化来治疗患有神经变性疾病的受试者的方法。 在本发明的一个实施方案中，胆碱能激动剂是尼古丁，胆碱酯酶是加兰他敏（相对弱的乙酰胆碱酯酶抑制剂和nAChRs的有效变构的增强配体）